63rd ASH Annual Meeting and Exposition
December 11-14, 2021
  • Population data for Aggressive NHL Management
  • Clinical Management of Aggressive B cell NHL
  • Real World evidence for CAR-T Management I
  • Real World evidence for CAR-T Management II

627. Aggressive Lymphomas: Clinical and Epidemiological: Population data for Aggressive NHL Management


Daniel A. Ermann, Victoria A. Vardell, Harsh Shah, et al.

The data shows an improved OS. This applies both to node-only disease and within certain subgroups of EN disease when RT is used in addition to first-line chemotherapy. See abstract for more info.



Andreas Kiesbye Øvlisen, Lasse H. Jakobsen, Kristian Hay Kragholm, et al.

NHL patients are at significantly higher risk for mental health problems compared to the general population. This is suggested by the prescribing data for psychotropic substances. See abstract for more info



Anita Kumar, Jason R. Westin, Stephen J. Schuster, et al.

A high proportion of 45 percent of clinical recurrences in asymptomatic patients is demonstrated radiographically. This emphasizes the value of surveillance CT imaging in DLBCL, especially in patients with advanced or high-risk disease. See abstract for more info



Freja Tang Severinsen, Laura Mors Haunstrup, Rasmus Kuhr Jensen, et al.

Patients who were not enrolled in a study had poorer survival even after adjusting for imbalances in age and disease risk category. See abstract for more info



Carmelo Carlo-Stella, Pier Luigi Luigi Zinzani, Murali Janakiram, et al.

In patients with R/R-DLBCL, Lonca + ibrutinib demonstrated encouraging antitumor activity at the dosages tested. The safety profile is manageable.

627. Aggressive Lymphomas: Clinical and Epidemiological: Clinical Management of Aggressive B cell NHL


Jakoba J Eertink, Gerben J.C Zwezerijnen, Sanne E Wiegers, et al.

According to the authors, radiomics features can increase the efficiency of clinical trials by only selecting poor prognosis patients. See more info in the abstract.



Matthew R Wilson, Toby A. Eyre, Amy A Kirkwood, et al.

In this extensive analysis of 1L R-CHOP patients, no evidence was found that EOT administration increased the risk of CNS relapse compared to i-HDMTX. See more info in the abstract.



Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, et al.

Excellent 5-year TTP (95%) and EFS (94%) were found in the multicenter NCI 9177 study in patients with Burkitt lymphoma and low- or medium-risk BL-IPI scores. Age is not prognostic with DA-EPOCH-R. In contrast, CNS /BM /PB involvement is prognostic in the BL-IPI groups.



Joachim Baech, Marianne Tang Severinsen, Andreas Kiesbye Øvlisen, et al.

Beyond the first year, patients treated with steroid-containing immunochemotherapy did not show a higher risk of DM than comparable comparator products. See more info in the abstract.



Adam Zayac, Daniel J Landsburg, Mitchell Hughes, et al.

See more info in the abstract



Paw Jensen, Lasse H. Jakobsen, Martin Bøgstede, et al.

For primary prophylaxis against glucocorticoid-induced osteoporosis in all lymphoma patient subgroups, alendronate has been shown to be clinically important, safe, and effective, with the greatest effect size in women.

627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management I


Geoffrey Shouse, Andy Kaempf, David Yashar, et al.

CIRS is predictive. The authors identify a composite index comprising four CIRS organ systems that has prognostic significance for r / r DLBCL in CAR-T recipients. More info in the abstract.



Frederick L. Locke, Caron Jacobson, Long Ma, PhD, et al.

No poorer Axi-cel efficacy results were observedt at ≥65 years of age, despite higher CRS and ICANS rates. Therefore, performance status, rather than age, should be considered in patient selection and treatment decisions.



Robin Sanderson, Andrea Kuhnl, Eleni Tholouli, et al.

For more info see abstract.



Imran Nizamuddin, Kevin A. David, Jonathon B. Cohen, et al.

For more info see abstract.



L. Elizabeth Budde, Adam J. Olszewski, Sarit Assouline, et al.

In heavily pretreated R/R aggressive B-NHL patients, including patients with previous CAR-T therapy, according to the study authors, M-Pola has promising efficacy and a favorable safety profile. The CRS rate was low and the majority were grade 1.



Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, et al.

The antibody-mediated response to vaccination in patients after treatment with anti-CD20 antibodies was significantly impaired over a long period of time. For more info see abstract.

627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management II


Ana Alarcon Tomas, Joshua A Fein, Shalev Fried, et al.

The most extensive and detailed experience of treatment outcomes post-CAR-T therapy are presented. For more info see abstract. New drugs may be preferable to traditional chemotherapy as the first treatment after CAR-T, even if survival is still poor. The authors present an instrument that provides information about the mortality risk in this difficult-to-treat population group.



Joanna C. Zurko, Narendranath Epperla, Imran Nizamuddin, et al.

The authors present the largest reported analysis of patients with aggressive B-cell lymphoma who develop PD post-CART. For more info see abstract.



Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, et al.

The results in this analysis of patients with R/R-aggressive BCL relapse after anti-CD19-CAR T cells are poor and show the need for further innovative treatment strategies.



Jennifer L. Crombie, Robert A. Redd, Victor A. Chow, et al.

For more info see abstract.



Susan Prockop, Laurence Gamelin, Rajani Dinavahi, et al.

Patients whose EBV + PTLD did not respond to rituximab (HCT) or rituximab ± CT (SOT) and who responded to Tabelecleucel had long-term survival and an OS benefit similar to those who achieved CR. Tabelecleucel was well tolerated.



Anna Santarsieri, Andrew Butler, William Gelson, et al.

Treatment of monomorphic DLBL patients primarily with RM rather than R chemotherapy does not seem to compromise the OS. The number of patients who die of non-lymphoma causes - before and after lymphoma treatment - is high with both treatment approaches. The OS compares poorly to age-adjusted non-PTLD SOT recipients. For more info see abstract.


  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos


Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.




Copyright 2024. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close